| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
This compound is a structural component of biological membranes, particularly in the brain and retina. It can be hydrolyzed by phospholipase A2 to release DHA, which serves as a precursor for neuroprotective signaling molecules (resolvins, protectins, maresins).
|
|---|---|
| ln Vitro |
In vitro, this phospholipid enhances membrane fluidity and permeability, promotes dynamic lipid interactions, and supports the organization of lipid rafts. It is used as a standard in lipidomics to study DHA-containing phospholipid metabolism and distribution.
|
| ln Vivo |
In animal studies, this compound is often administered via dietary supplementation to enrich tissues with DHA. It is used in animal models of neurodegenerative disease (e.g., Alzheimer's) to study the effects of DHA-phospholipids on cognitive function and neuroinflammation.
|
| Enzyme Assay |
Non-cell assays are performed using Palmitoyldocosahexaenoyl phosphatidylcholine in liposome or model membrane systems. It is used to study phospholipase A2 kinetics by monitoring free fatty acid release via GC-MS, and to investigate membrane biophysics using techniques such as fluorescence anisotropy or NMR.
|
| Cell Assay |
For cell studies, the compound is typically delivered to cells via liposomes or dissolved in culture medium with a carrier (e.g., fatty acid-free BSA). It is used to study DHA incorporation into cellular membranes and its effects on lipid raft organization in neuronal cell lines (e.g., SH-SY5Y, PC12).
|
| Animal Protocol |
Animal experiments typically involve feeding rodents a diet supplemented with Palmitoyldocosahexaenoyl phosphatidylcholine (1-5% by weight). Tissues (brain, liver, retina) are collected to analyze DHA levels and lipid raft composition. Behavioral tests (Morris water maze) are used to assess cognitive outcomes.
|
| ADME/Pharmacokinetics |
As a membrane phospholipid, it is absorbed from the diet and incorporated into lipoproteins. It is preferentially distributed to the brain and retina where DHA is highly enriched. It has a long half-life in tissues (weeks) and is slowly turned over by phospholipases and acyltransferases.
|
| Toxicity/Toxicokinetics |
Palmitoyldocosahexaenoyl phosphatidylcholine is generally regarded as safe as it is a natural component of fish oils and biological membranes. High dietary intake of DHA-containing phospholipids is associated with no significant adverse effects. It is non-toxic at physiological concentrations.
|
| Additional Infomation |
1-Hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docohexanoyl)-sn-glycerol-3-phosphocholine is a phosphatidylcholine 38:6, wherein the acyl groups at C-1 and C-2 are hexadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docohexanoyl, respectively. It is a mouse metabolite. Its function is related to hexadecanoic acid and all-cis-docohexano-4,7,10,13,16,19-hexaenoic acid.
This compound is used as a research standard in lipidomics for LC-MS analysis. It is studied for potential therapeutic applications in Alzheimer's disease, age-related macular degeneration, and other conditions characterized by DHA deficiency and neuroinflammation. It is not an approved drug. |
| Molecular Formula |
C46H80NO8P
|
|---|---|
| Molecular Weight |
806.10
|
| Exact Mass |
805.562
|
| CAS # |
59403-54-2
|
| PubChem CID |
6441886
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
12.678
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
56
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
| InChi Key |
IESVDEZGAHUQJU-ZLBXKVHBSA-N
|
| InChi Code |
InChI=1S/C46H80NO8P/c1-6-8-10-12-14-16-18-20-21-22-23-24-25-27-29-31-33-35-37-39-46(49)55-44(43-54-56(50,51)53-41-40-47(3,4)5)42-52-45(48)38-36-34-32-30-28-26-19-17-15-13-11-9-7-2/h8,10,14,16,20-21,23-24,27,29,33,35,44H,6-7,9,11-13,15,17-19,22,25-26,28,30-32,34,36-43H2,1-5H3/b10-8-,16-14-,21-20-,24-23-,29-27-,35-33-/t44-/m1/s1
|
| Chemical Name |
[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2405 mL | 6.2027 mL | 12.4054 mL | |
| 5 mM | 0.2481 mL | 1.2405 mL | 2.4811 mL | |
| 10 mM | 0.1241 mL | 0.6203 mL | 1.2405 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
